New orphan drug (clobazam-Onfi) approved for Lennox-Gastaut seizures
Some types of seizures are difficult to control. This is certainly true of Lennox-Gastaut syndrome. the FDA has approved cobazam (Onfi) as add-on therapy to treat seizures in children 2 years or older and adults. This is called an orphan drug since it is approved to treat a disease or condition that impacts 200,000 people or less.
Lennox-Gastaut is a particularly challenging kind of epilepsy for those suffering with the condition as well for clinicians trying to treat it. This syndrome usually starts at roughly 4 years of age and can also be caused by head injuries, central nervous system infections and metabolic conditions.
Additional information can be found at www.fda.gov
Approval Date:
Mon, 10/24/2011
Company:
Lundbeck